Observational 24‐week study to assess clinical response to upadacitinib posttrial in patients with moderate‐to‐severe atopic dermatitis

Observational 24‐week study to assess clinical response to upadacitinib posttrial in patients with moderate‐to‐severe atopic dermatitis

Abstract Background The oral anti‐janus kinase 1 inhibitor upadacitinib has shown a good efficacy–safety profile in the treatment of moderate‐to‐severe atopic dermatitis (AD) in clinical trials; however, few data from real clinical practice have been published so far. Objectives To evaluate the effi...

Full description

Bibliographic Details
Main Authors: Ana Batalla, Hae Jin Suh‐Oh, Gregorio Carretero Hernández, Javier Miquel‐Miquel, Rafael Botella‐Estrada, Antonio Martorell‐Calatayud, Virginia Sanz‐Motilva, Ignasi Figueras‐Nart, Angeles Flórez
Format: Article
Language:English
Published: Wiley 2023-09-01
Series:JEADV Clinical Practice
Subjects:
atopic dermatitis
treatment
upadacitinib
Online Access:https://doi.org/10.1002/jvc2.179

Internet

https://doi.org/10.1002/jvc2.179

Similar Items